Literature DB >> 24748932

Glycemic control indicators in patients with neonatal diabetes mellitus.

Shigeru Suzuki1, Masafumi Koga1.   

Abstract

Neonatal diabetes mellitus (NDM) is a type of diabetes mellitus caused by genetic abnormality which develops in insulin dependent state within 6 mo after birth. HbA1c is widely used in clinical practice for diabetes mellitus as the gold standard glycemic control indicator; however, fetal hemoglobin (HbF) is the main hemoglobin in neonates and so HbA1c cannot be used as a glycemic control indicator in NDM. Glycated albumin (GA), another glycemic control indicator, is not affected by HbF. We reported that GA can be used as a glycemic control indicator in NDM. However, it was later found that because of increased metabolism of albumin, GA shows an apparently lower level in relation to plasma glucose in NDM; measures to solve this problem were needed. In this review, we outlined the most recent findings concerning glycemic control indicators in neonates or NDM.

Entities:  

Keywords:  1,5-anhydroglucitol; Fructosamine; Glycated albumin; Glycemic control; HbA1c; Neonatal diabetes mellitus

Year:  2014        PMID: 24748932      PMCID: PMC3990320          DOI: 10.4239/wjd.v5.i2.198

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  78 in total

Review 1.  Clinical impact of glycated albumin as another glycemic control marker.

Authors:  Masafumi Koga; Soji Kasayama
Journal:  Endocr J       Date:  2010-08-17       Impact factor: 2.349

2.  The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method.

Authors:  Curt L Rohlfing; Shawn M Connolly; Jack D England; Steven E Hanson; Christina M Moellering; Janielle R Bachelder; Randie R Little
Journal:  Am J Clin Pathol       Date:  2008-05       Impact factor: 2.493

3.  1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease.

Authors:  Masafumi Koga; Jun Murai; Hiroshi Saito; Mikio Mukai; Daishu Toya; Nobuyoshi Tanaka; Hideo Kanehara; Yukihiro Bando; Soji Kasayama
Journal:  Ann Clin Biochem       Date:  2010-08-24       Impact factor: 2.057

4.  Determination of glycated hemoglobin in clinically silent hemoglobin variants.

Authors:  Wolfgang J Schnedl; Theresa Lahousen; Thomas Lang; Rainer W Lipp; Satoshi Yonehara; Satoshi Fukunaga; Toshihiro Imai; Randie R Little
Journal:  Diabetes Metab Res Rev       Date:  2004 Nov-Dec       Impact factor: 4.876

5.  Serum levels of 1,5-anhydro-D-glucitol during the normal and diabetic pregnancy and puerperium.

Authors:  M Tetsuo; T Hamada; K Yoshimatsu; J Ishimatsu; T Matsunaga
Journal:  Acta Obstet Gynecol Scand       Date:  1990       Impact factor: 3.636

6.  Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes.

Authors:  Kazutomi Yoshiuchi; Munehide Matsuhisa; Naoto Katakami; Yoshihisa Nakatani; Kenya Sakamoto; Takaaki Matsuoka; Yutaka Umayahara; Keisuke Kosugi; Hideaki Kaneto; Yoshimitsu Yamasaki; Masatsugu Hori
Journal:  Endocr J       Date:  2008-04-30       Impact factor: 2.349

7.  Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period.

Authors:  A M Patch; S E Flanagan; C Boustred; A T Hattersley; S Ellard
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

8.  Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.

Authors:  T Yamanouchi; N Ogata; T Tagaya; T Kawasaki; N Sekino; H Funato; L Akaoka; H Miyashita
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

9.  Glycosylated haemoglobin and glycosylated albumin in non-diabetic and diabetic mothers, and their babies.

Authors:  W G John; A M Webb; A E Jones
Journal:  Diabet Med       Date:  1985-03       Impact factor: 4.359

10.  Influence of serum proteins on fructosamine concentration in multiple myeloma.

Authors:  M P Montagna; F Laghi; G Cremona; C Zuppi; G Barbaresi; M L Castellana
Journal:  Clin Chim Acta       Date:  1991-12-31       Impact factor: 3.786

View more
  4 in total

Review 1.  Utility of different glycemic control metrics for optimizing management of diabetes.

Authors:  Klaus-Dieter Kohnert; Peter Heinke; Lutz Vogt; Eckhard Salzsieder
Journal:  World J Diabetes       Date:  2015-02-15

2.  Effects of a Follow-On Formula Containing Isomaltulose (Palatinose™) on Metabolic Response, Acceptance, Tolerance and Safety in Infants: A Randomized-Controlled Trial.

Authors:  M Fleddermann; A Rauh-Pfeiffer; H Demmelmair; L Holdt; D Teupser; B Koletzko
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

3.  Neonatal diabetes mellitus due to a novel variant in the INS gene.

Authors:  Sarah E Laurenzano; Cory McFall; Linda Nguyen; Dipal Savla; Nicole G Coufal; Meredith S Wright; Mari Tokita; David Dimmock; Stephen F Kingsmore; Ron S Newfield
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-08-01

4.  Correlation between hyperglycemia and glycated albumin with retinopathy of prematurity.

Authors:  Ana C Almeida; Gabriela A Silva; Gabriele Santini; Margarida Brízido; Miguel Correia; Constança Coelho; Luís Miguel Borrego
Journal:  Sci Rep       Date:  2021-11-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.